PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.95 EUR | +0.34% |
|
+0.34% | -35.87% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.95
EUR
Average target price
6.85
EUR
Spread / Average Target
+132.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.39% | 102B | |
| +2.61% | 96.09B | |
| -1.02% | 22.05B | |
| -18.14% | 20.81B | |
| -6.87% | 19.06B | |
| -40.70% | 16.05B | |
| -26.89% | 14.01B | |
| +1.12% | 13.38B | |
| +22.25% | 11.01B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- European ADRs Move Lower in Monday Trading
